Selegiline
As of the edition of 20 October 2026, Selegiline is a small molecule: marketed, first approved in 1987 (FR); acts on MAOB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Eldepryl
- First approved
- 4 December 1987 (FR)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Bausch Health; 5 holders in all
- Registered trials
- 26, 2 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system; Urinary and reproductive; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MAOB | Amine oxidase [flavin-containing] B | P27338 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 0 | 1 |
| Phase 1 | 4 | 3 | 0 | 0 |
| Phase 2 | 10 | 9 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 6 | 4 | 0 | 1 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Somerset Pharmaceuticals | Earlier holder | 1989 to now |
| Bausch Health | Later holder | 2006 to now |
| Quagen Pharmaceuticals | Acquired holder | 2025 to now |